ImmunityBio, Inc.
IBRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,329 | $2,345 | $2,568 | $1,785 |
| - Cash | $60 | $138 | $61 | $143 |
| + Debt | $41 | $535 | $526 | $504 |
| Enterprise Value | $2,310 | $2,743 | $3,034 | $2,146 |
| Revenue | $32 | $26 | $17 | $8 |
| % Growth | 21.3% | 60% | 118.7% | – |
| Gross Profit | $28 | $26 | $16 | $8 |
| % Margin | 87.1% | 99.5% | 99.6% | 100% |
| EBITDA | -$36 | -$60 | -$97 | -$40 |
| % Margin | -111.6% | -225.3% | -588.5% | -531.3% |
| Net Income | -$67 | -$93 | -$130 | -$59 |
| % Margin | -209.8% | -350.3% | -784.9% | -783.4% |
| EPS Diluted | -0.071 | -0.1 | -0.15 | -0.09 |
| % Growth | 29% | 33.3% | -66.7% | – |
| Operating Cash Flow | -$69 | -$80 | -$86 | -$85 |
| Capital Expenditures | $0 | -$1 | -$1 | -$2 |
| Free Cash Flow | -$69 | -$81 | -$87 | -$87 |